Hepatotoxicity of Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Randomized Controlled Trials

Background. Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most widely used medication in several countries, including Thailand. NSAIDs have been associated with hepatic side effects; however, the frequency of these side effects is uncertain. Aim of the Review. To systematically review publis...

Full description

Saved in:
Bibliographic Details
Main Authors: Pajaree Sriuttha, Buntitabhon Sirichanchuen, Unchalee Permsuwan
Format: Article
Language:English
Published: Wiley 2018-01-01
Series:International Journal of Hepatology
Online Access:http://dx.doi.org/10.1155/2018/5253623
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849434731907645440
author Pajaree Sriuttha
Buntitabhon Sirichanchuen
Unchalee Permsuwan
author_facet Pajaree Sriuttha
Buntitabhon Sirichanchuen
Unchalee Permsuwan
author_sort Pajaree Sriuttha
collection DOAJ
description Background. Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most widely used medication in several countries, including Thailand. NSAIDs have been associated with hepatic side effects; however, the frequency of these side effects is uncertain. Aim of the Review. To systematically review published literature on randomized, controlled trials that assessed the risk of clinically significant hepatotoxicity associated with NSAIDs. Methods. Searches of bibliographic databases EMBASE, PubMed, and the Cochrane Library were conducted up to July 30, 2016, to identify randomized controlled trials of ibuprofen, naproxen, diclofenac, piroxicam, meloxicam, mefenamic acid, indomethacin, celecoxib, and etoricoxib in adults with any disease that provide information on hepatotoxicity outcomes. Results. Among the 698 studies, 18 studies met the selection criteria. However, only 8 studies regarding three NSAIDs (celecoxib, etoricoxib, and diclofenac) demonstrated clinically significant hepatotoxic evidence based on hepatotoxicity justification criteria. Of all the hepatotoxicity events found from the above-mentioned three NSAIDs, diclofenac had the highest proportion, which ranged from 0.015 to 4.3 (×10−2), followed by celecoxib, which ranged from 0.13 to 0.38 (×10−2), and etoricoxib, which ranged from 0.005 to 0.930 (×10−2). Conclusion. Diclofenac had higher rates of hepatotoxic evidence compared to other NSAIDs. Hepatotoxic evidence is mostly demonstrated as aminotransferase elevation, while liver-related hospitalization or discontinuation was very low.
format Article
id doaj-art-e40db5511a8d4111b8d218445b3eb637
institution Kabale University
issn 2090-3448
2090-3456
language English
publishDate 2018-01-01
publisher Wiley
record_format Article
series International Journal of Hepatology
spelling doaj-art-e40db5511a8d4111b8d218445b3eb6372025-08-20T03:26:33ZengWileyInternational Journal of Hepatology2090-34482090-34562018-01-01201810.1155/2018/52536235253623Hepatotoxicity of Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Randomized Controlled TrialsPajaree Sriuttha0Buntitabhon Sirichanchuen1Unchalee Permsuwan2Faculty of Pharmacy, Chiang Mai University, Chiang Mai, ThailandFaculty of Pharmacy, Chiang Mai University, Chiang Mai, ThailandFaculty of Pharmacy, Chiang Mai University, Chiang Mai, ThailandBackground. Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most widely used medication in several countries, including Thailand. NSAIDs have been associated with hepatic side effects; however, the frequency of these side effects is uncertain. Aim of the Review. To systematically review published literature on randomized, controlled trials that assessed the risk of clinically significant hepatotoxicity associated with NSAIDs. Methods. Searches of bibliographic databases EMBASE, PubMed, and the Cochrane Library were conducted up to July 30, 2016, to identify randomized controlled trials of ibuprofen, naproxen, diclofenac, piroxicam, meloxicam, mefenamic acid, indomethacin, celecoxib, and etoricoxib in adults with any disease that provide information on hepatotoxicity outcomes. Results. Among the 698 studies, 18 studies met the selection criteria. However, only 8 studies regarding three NSAIDs (celecoxib, etoricoxib, and diclofenac) demonstrated clinically significant hepatotoxic evidence based on hepatotoxicity justification criteria. Of all the hepatotoxicity events found from the above-mentioned three NSAIDs, diclofenac had the highest proportion, which ranged from 0.015 to 4.3 (×10−2), followed by celecoxib, which ranged from 0.13 to 0.38 (×10−2), and etoricoxib, which ranged from 0.005 to 0.930 (×10−2). Conclusion. Diclofenac had higher rates of hepatotoxic evidence compared to other NSAIDs. Hepatotoxic evidence is mostly demonstrated as aminotransferase elevation, while liver-related hospitalization or discontinuation was very low.http://dx.doi.org/10.1155/2018/5253623
spellingShingle Pajaree Sriuttha
Buntitabhon Sirichanchuen
Unchalee Permsuwan
Hepatotoxicity of Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Randomized Controlled Trials
International Journal of Hepatology
title Hepatotoxicity of Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Randomized Controlled Trials
title_full Hepatotoxicity of Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Randomized Controlled Trials
title_fullStr Hepatotoxicity of Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Randomized Controlled Trials
title_full_unstemmed Hepatotoxicity of Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Randomized Controlled Trials
title_short Hepatotoxicity of Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Randomized Controlled Trials
title_sort hepatotoxicity of nonsteroidal anti inflammatory drugs a systematic review of randomized controlled trials
url http://dx.doi.org/10.1155/2018/5253623
work_keys_str_mv AT pajareesriuttha hepatotoxicityofnonsteroidalantiinflammatorydrugsasystematicreviewofrandomizedcontrolledtrials
AT buntitabhonsirichanchuen hepatotoxicityofnonsteroidalantiinflammatorydrugsasystematicreviewofrandomizedcontrolledtrials
AT unchaleepermsuwan hepatotoxicityofnonsteroidalantiinflammatorydrugsasystematicreviewofrandomizedcontrolledtrials